tbuckley/cabot-search huggingface dataset:
Invaginated fibrokeiratoma with matrix differentiation: a new histological variant of acquired fibrokeratoma
Authors: C. PERRIN, R. BARAN
Journal: British Journal of Dermatology (1994)

Journal Article Invaginated fibrokeiratoma with matrix differentiation: a new histological variant of acquired fibrokeratoma Get access C. PERRIN, C. PERRIN Department of Pathology, Hospital Pasteur. 06002 Nice, France Search for other works by this author on: Oxford Academic Google Scholar R. BARAN R. BARAN Department of Dermatology, Cannes General Hospital. 06407 Cannes, France Dr R. Baran, 42, Rue des Serbcs, 06400 Cannes, Pranee. Search for other works by this author on: Oxford Academic Google Scholar British Journal of Dermatology, Volume 130, Issue 5, 1 May 1994, Pages 654–657, https://doi.org/10.1111/j.1365-2133.1994.tb13115.x Published: 01 May 1994 Article history Accepted: 14 October 1993 Published: 01 May 1994
The Role of Dexpanthenol in Postoperative Ileus
Authors: Alvin L. Watne
Journal: JAMA (1962)

The effectiveness of dexpanthenol in preventing and treating postoperative ileus was tested in observations on 101 patients who underwent major surgery under general anesthesia. The test group of 50 patients who received dexpanthenol was compared with a contratest group who received sodium chloride. No significant difference was found between the 2 groups as to incidence of postoperative complications, duration of hospitalization, or other criteria of gastrointestinal function.
Effect of Pioglitazone Compared With Glimepiride on Carotid Intima-Media Thickness in Type 2 Diabetes
Authors: Theodore Mazzone, Peter M. Meyer, Steven B. Feinstein, Michael H. Davidson, George T. Kondos, Ralph B. D’Agostino, Alfonso Perez, Jean-Claude Provost, Steven M. Haffner
Journal: JAMA (2006)

Carotid artery intima-media thickness (CIMT) is a marker of coronary atherosclerosis and independently predicts cardiovascular events, which are increased in type 2 diabetes mellitus (DM). While studies of relatively short duration have suggested that thiazolidinediones such as pioglitazone might reduce progression of CIMT in persons with diabetes, the results of longer studies have been less clear.To evaluate the effect of pioglitazone vs glimepiride on changes in CIMT of the common carotid artery in patients with type 2 DM.Randomized, double-blind, comparator-controlled, multicenter trial in patients with type 2 DM conducted at 28 clinical sites in the multiracial/ethnic Chicago metropolitan area between October 2003 and May 2006. The treatment period was 72 weeks (1-week follow-up). CIMT images were captured by a single ultrasonographer at 1 center and read by a single treatment-blinded reader using automated edge-detection technology. Participants were 462 adults (mean age, 60 [SD, 8.1] years; mean body mass index, 32 [SD, 5.1]) with type 2 DM (mean duration, 7.7 [SD, 7.2] years; mean glycosylated hemoglobin [HbA1c] value, 7.4% [SD, 1.0%]), either newly diagnosed or currently treated with diet and exercise, sulfonylurea, metformin, insulin, or a combination thereof.Pioglitazone hydrochloride (15-45 mg/d) or glimepiride (1-4 mg/d) as an active comparator.Absolute change from baseline to final visit in mean posterior-wall CIMT of the left and right common carotid arteries.Mean change in CIMT was less with pioglitazone vs glimepiride at all time points (weeks 24, 48, 72). At week 72, the primary end point of progression of mean CIMT was less with pioglitazone vs glimepiride (-0.001 mm vs +0.012 mm, respectively; difference, -0.013 mm; 95% confidence interval, -0.024 to -0.002; P = .02). Pioglitazone also slowed progression of maximum CIMT compared with glimepiride (0.002 mm vs 0.026 mm, respectively, at 72 weeks; difference, -0.024 mm; 95% confidence interval, -0.042 to -0.006; P = .008). The beneficial effect of pioglitazone on mean CIMT was similar across prespecified subgroups based on age, sex, systolic blood pressure, duration of DM, body mass index, HbA(1c) value, and statin use.Over an 18-month treatment period in patients with type 2 DM, pioglitazone slowed progression of CIMT compared with glimepiride.clinicaltrials.gov Identifier: NCT00225264
Are problem drinkers dangerous drivers? An investigation of arrest for drinking and driving, serum gamma glutamyltranspeptidase activities, blood alcohol concentrations, and road traffic accidents: the Tayside Safe Driving Project.
Authors: J A Dunbar, S A Ogston, A Ritchie, M S Devgun, J Hagart, B T Martin
Journal: BMJ (1985)

Serum gamma glutamyltranspeptidase activity was measured in 440 drivers at the time of arrest for driving under the influence of alcohol. The results were compared with information gathered by the arresting police officer. One third of drivers over the age of 30 had abnormal gamma glutamyltranspeptidase activities at the time of arrest. Among drivers who required a driving license for their work, and older drivers, a disproportionately high number had raised gamma glutamyltranspeptidase activities indicating problem drinking. In drivers over the age of 30 a strong association was found between gamma glutamyltranspeptidase activities and road traffic accidents but not alcohol concentrations or previous convictions. These findings argue against the Department of Transport9s criteria for high risk offenders and indicate a clear need for new measures against problem drinkers among drinking and driving offenders.
The psychoanalytic view
Authors: E. R. Gonzalez
Journal: JAMA (1980)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Waldenström’s macroglobulinemia harbors a unique proteome where Ku70 is severely underexpressed as compared with other B-lymphoproliferative disorders
Authors: A Perrot, C Pionneau, N Azar, C Baillou, F M Lemoine, V Leblond, H Merle-Béral, M-C Béné, R Herbrecht, S Bahram, L Vallat
Journal: Blood Cancer Journal (2012)

Waldenström's macroglobulinemia (WM) is a clonal B-cell lymphoproliferative disorder (LPD) of post-germinal center nature. Despite the fact that the precise molecular pathway(s) leading to WM remain(s) to be elucidated, a hallmark of the disease is the absence of the immunoglobulin heavy chain class switch recombination. Using two-dimensional gel electrophoresis, we compared proteomic profiles of WM cells with that of other LPDs. We were able to demonstrate that WM constitutes a unique proteomic entity as compared with chronic lymphocytic leukemia and marginal zone lymphoma. Statistical comparisons of protein expression levels revealed that a few proteins are distinctly expressed in WM in comparison with other LPDs. In particular we observed a major downregulation of the double strand repair protein Ku70 (XRCC6); confirmed at both the protein and RNA levels in an independent cohort of patients. Hence, we define a distinctive proteomic profile for WM where the downregulation of Ku70-a component of the non homologous end-joining pathway-might be relevant in disease pathophysiology.
Long-term prognosis in patients with psoriasis
Authors: W. Gulliver
Journal: British Journal of Dermatology (2008)

Psoriasis is a chronic, inflammatory, immune-mediated skin disease associated with substantial comorbidity. Traditional comorbid conditions include psychological/psychiatric disorders, psoriatic arthritis and inflammatory bowel disease. Increasingly, an association with metabolic dysfunction, including obesity and the metabolic syndrome, and cardiovascular disease, with consequent effects on morbidity and mortality, has been recognized in psoriasis. The underlying inflammatory mechanisms of both psoriasis and psoriasis-associated comorbidities involve mediation by proinflammatory T-helper type 1 cytokines. For effective management of psoriasis and related comorbidities, an integrated approach targeting both cutaneous and systemic inflammation may be beneficial, and strategies to improve overall management of the patient should be encouraged to reduce the disease burden. This paper discusses the emerging role of biological agents in this approach, and offers an appreciation of the role of existing anti-psoriasis and adjunctive therapies.
Thyroid disease in pustulosis palmoplantaris
Authors: T. AGNER, J.H. SINDRUP, MIMI HoIER-MADSEN, L. HEGEDUS
Journal: British Journal of Dermatology (1989)

An increased frequency of thyroid autoantibodies has been reported in patients with palmar and plantar pustulosis (PPP). This study was undertaken to determine the frequency and type of thyroid disease in 32 patients with this disease compared with a control group. Thyroid disease was demonstrated in 53% of the patients with PPP as compared to 16% in the matched control group. Fourteen patients with PPP had an enlarged thyroid and in six there were thyroid autoantibodies. There appears to be an increased incidence of goitre and thyroid autoantibodies in PPP with a decrease in the level of the thyroid hormones.
Point-of-care testing versus standard practice for chlamydia: a new approach to assessing the public health effect of rapid testing and treatment at local level
Authors: Catherine M Lowndes, Ellie Sherrard-Smith, Ciara Dangerfield, Yoon H Choi, Nathan Green, Mark Jit, Rob D Marshall, Catherine Mercer, Emma Harding-Esch, Anthony Nardone, Rebecca Howell-Jones, John Bason, Owen A Johnson, Christopher P Price, Charlotte A Gaydos, S Tariq Sadiq, Peter J White
Journal: The Lancet (2014)
Haemodynamic effects of buprenorphine after heart surgery.
Authors: F L Rosenfeldt, B Houston, D Thompson, N Naqui, A D Malcolm, B T Williams, D J Coltart
Journal: BMJ (1978)

The effect of buprenorphine on the cardiovascular system was examined in 11 patients during the period of reduced cardiac reserve after open-heart surgery. Within 10 minutes of giving the full analgesic dose (5 microgram/kg) intravenously the mean heart rate had fallen significantly by six beats/min. Although in two patients the mean arterial pressure fell by 24 mm Hg, there was no overall change in mean arterial pressure, cardiac output, or peripheral resistance. In a further six patients buprenorphine was used successfully as the sole analgesic after open-heart surgery. Buprenorphine appears to be safer than morphine for use in patients with reduced cardiac reserve and is of similar analgesic efficacy.
958 NO EVIDENCE OF R7128 DRUG RESISTANCE AFTER UP TO 4 WEEKS TREATMENT OF GT 1, 2 AND 3 HEPATITIS C VIRUS INFECTED INDIVIDUALS
Authors: S. Le Pogam, A. Seshaadri, A. Kosaka, S. Hu, A. Beard, S. Julian, C. Nick, I. Najera
Journal: Journal of Hepatology (2009)
Digital infarcts showing microangiopathy in adult dermatomyositis suggest severe pulmonary involvement and poor prognosis
Authors: J-W. Tjiu, S-J. Lin, L-F. Wang, J-Y. Shih, C-J. Yu, C-W. Liang, C-Y. Chu
Journal: British Journal of Dermatology (2004)

Journal Article Digital infarcts showing microangiopathy in adult dermatomyositis suggest severe pulmonary involvement and poor prognosis Get access J‐W. Tjiu, J‐W. Tjiu Departments of Dermatology, *Internal Medicine and †Pathology, National Taiwan University Hospital, and National Taiwan University College of Medicine, 7 Chung‐Shan South Road, Taipei 100, Taiwan Chia‐Yu Chu, MD. E‐mail: chiayuju@seed.net.tw Search for other works by this author on: Oxford Academic Google Scholar S‐J. Lin, S‐J. Lin Departments of Dermatology, *Internal Medicine and †Pathology, National Taiwan University Hospital, and National Taiwan University College of Medicine, 7 Chung‐Shan South Road, Taipei 100, Taiwan Chia‐Yu Chu, MD. E‐mail: chiayuju@seed.net.tw Search for other works by this author on: Oxford Academic Google Scholar L‐F. Wang, L‐F. Wang Departments of Dermatology, *Internal Medicine and †Pathology, National Taiwan University Hospital, and National Taiwan University College of Medicine, 7 Chung‐Shan South Road, Taipei 100, Taiwan Chia‐Yu Chu, MD. E‐mail: chiayuju@seed.net.tw Search for other works by this author on: Oxford Academic Google Scholar J‐Y. Shih, J‐Y. Shih Departments of Dermatology, *Internal Medicine and †Pathology, National Taiwan University Hospital, and National Taiwan University College of Medicine, 7 Chung‐Shan South Road, Taipei 100, Taiwan Chia‐Yu Chu, MD. E‐mail: chiayuju@seed.net.tw Search for other works by this author on: Oxford Academic Google Scholar C‐J. Yu, C‐J. Yu Departments of Dermatology, *Internal Medicine and †Pathology, National Taiwan University Hospital, and National Taiwan University College of Medicine, 7 Chung‐Shan South Road, Taipei 100, Taiwan Chia‐Yu Chu, MD. E‐mail: chiayuju@seed.net.tw Search for other works by this author on: Oxford Academic Google Scholar C‐W. Liang, C‐W. Liang Departments of Dermatology, *Internal Medicine and †Pathology, National Taiwan University Hospital, and National Taiwan University College of Medicine, 7 Chung‐Shan South Road, Taipei 100, Taiwan Chia‐Yu Chu, MD. E‐mail: chiayuju@seed.net.tw Search for other works by this author on: Oxford Academic Google Scholar C‐Y. Chu C‐Y. Chu Departments of Dermatology, *Internal Medicine and †Pathology, National Taiwan University Hospital, and National Taiwan University College of Medicine, 7 Chung‐Shan South Road, Taipei 100, Taiwan Chia‐Yu Chu, MD. E‐mail: chiayuju@seed.net.tw Search for other works by this author on: Oxford Academic Google Scholar British Journal of Dermatology, Volume 150, Issue 6, 1 June 2004, Pages 1214–1216, https://doi.org/10.1111/j.1365-2133.2004.05979.x Published: 01 June 2004
NASAL CYSTOMATA—REPORT OF TWO CASES.Read before the Section of Laryngology, Washington Meeting American Medical Association, May, 1891.
Authors: C. W. RICHARDSON
Journal: JAMA (1891)

Cystic tumors involving the mucous membrane of the nasal passages,<i>i. e.</i>, true retention cysts, are very rare, if one must form his opinion from the meagre number of reported cases, and the treatment received by this subject—or not received—in most of the classical works upon rhinology. Many of our standard authorities make no mention of this subject, either under a special caption, or under the general subject of mucous polyps. Bosworth in his great work upon the nose devotes one page and a half to the consideration of this neoplasm. Watson and Sajous devote a small space to the consideration of this growth, both referring to its rarity. Wagner reports Leffert's case<i>in extenso</i>. Seiler, in a few lines, speaks of having seen this form of neoplasm and describes it "as large sessile cysts filled with the watery mucous and springing from lower border of inferior turbinate." McKenzie, Brown,
Mitral-Valve Endocarditis
Authors: C Firschke, A Schömig
Journal: New England Journal of Medicine (2001)

Figure 1. A 56-year-old man presented with severe lumbar pain, a seven-week history of fever (temperature as high as 39°C), a 10-kg weight loss, and a recent history of treatment with cephalosporins. He had a herniated L4–L5 intervertebral disk and hypertensive heart disease with a dilated left ventricle, reduced left ventricular function, and mild-to-moderate mitral regurgitation. Examination disclosed a grade 3/6 holosystolic murmur and evidence of sciatica. The serum level of C-reactive protein (12.1 mg per deciliter) and the leukocyte count (15,400 per cubic millimeter) were elevated. Blood cultures were negative. Lumbosacral magnetic resonance imaging and scintigraphy showed no specific . . .
Stable expression of cDNA encoding the human interleukin 2 receptor in eukaryotic cells.
Authors: W C Greene, R J Robb, P B Svetlik, C M Rusk, J M Depper, W J Leonard
Journal: The Journal of Experimental Medicine (1985)

Human interleukin 2 (IL-2) receptor cDNA derived from HUT 102B2 cells was stably expressed in murine L cells. These L cell transfectants (a) displayed surface receptors of the aberrant size of the IL-2 receptors on HUT 102B2 cells, (b) did not respond to exogenous IL-2 with augmented proliferation, and (c) expressed low affinity but not high affinity receptors for IL-2.
Immune response to a hepatitis C virus nonstructural protein in chronic hepatitis C virus infection
Authors: Sun-Lung Tsai, Pei-Jer Chen, Lih-Hwa Hwang, Jia-Horng Kao, Jyh-Hsiung Huang, Tong-Hsuan Chang, Ding-Shinn Chen
Journal: Journal of Hepatology (1994)
Cyclosporin A: Drug discontinuation for the management of long-term toxicity after liver transplantation
Authors: C Chan, K DasGupta, A L Baker
Journal: Hepatology (1996)

After liver transplantation, long-term cyclosporin A (CsA) administration is commonly complicated by renal insufficiency and other side effects. To manage these problems, 1.5 to 2.0 mg x kg(-1) x day(-1) of azathioprine for at least 6 weeks was prescribed; CsA was then discontinued or reduced to < or = 2.5 mg x kg(-1) x day(-1) for several months. The dose of prednisone was kept constant. CsA was discontinued in 14 patients because of nephrotoxicity (three or more serum creatinine levels of > or = 1.5 mg/dL), in 1 patient because of headaches and in 1 patient because of a generalized sensory neuropathy; 1 patient refused to continue taking the drug. The CsA dose was reduced in 13 patients, 12 because of nephrotoxicity and 1 because of headaches. One patient in whom administration of CsA was stopped developed azathioprine hepatotoxicity, whereas 1 patient whose dose was reduced developed acute cellular rejection. These complications were controlled by discontinuing azathioprine and reinitiating CsA. In the patients in whom CsA was discontinued, the mean serum creatinine level decreased from 2.42 +/- 0.48 to 1.72 +/- 0.39 mg/dL (P = .00004); in the patients in whom CsA was reduced, the mean serum creatinine level decreased less markedly. This report suggests that discontinuation of CsA along with increased doses of azathioprine is safe for some patients and may be effective in managing CsA-related nephrotoxicity and other side effects after liver transplantation. Additional studies are needed to determine whether this approach is safe and effective for the growing number of post-transplantation patients who may be candidates for such therapy.
DIFFERENTIAL CLINICAL IMPACT OF THE ANGIOGRAPHIC MECHANISMS UNDERLYING PERIPROCEDURAL MYOCARDIAL INFARCTION AFTER DRUG-ELUTING STENT IMPLANTATION
Authors: Duk-Woo Park, Young-Hak Kim, Sung-Cheol Yun, Jung-Min Ahn, Jong-Young Lee, Soo-Jin Kang, Seung-Whan Lee, Cheol Whan Lee, Seong-Wook Park, Seung-Jung Park
Journal: Journal of the American College of Cardiology (2014)
Microneurographic studies of the mechanisms of sympathetic nerve responses to static exercise in humans.
Authors: A L Mark, R G Victor, C Nerhed, B G Wallin
Journal: Circulation Research (1985)

The purpose of this study was to determine the contribution of muscle afferents and central command in regulating sympathetic nerve activity during static exercise in humans. In 20 healthy subjects, we recorded heart rate, arterial pressure, and efferent sympathetic nerve activity in the leg during arm exercise. Microelectrodes were inserted percutaneously into a fascicle of the peroneal nerve to measure sympathetic discharge to muscle. Measurements were obtained in nine subjects during sustained handgrip (30% maximal voluntary contraction) followed by relaxation or by arrested circulation of the forearm. Heart rate and arterial pressure increased during the first and second minutes of handgrip. Muscle sympathetic nerve activity increased from 261 +/- 46 to 504 +/- 97 units (mean +/- SE; units = burst frequency X amplitude; P less than 0.05) during the second minute of handgrip. During forearm ischemia following handgrip, heart rate returned promptly to control, whereas arterial pressure and muscle sympathetic nerve activity (631 +/- 115 units) remained elevated. In contrast, muscle sympathetic nerve activity returned toward control during relaxation without arrested circulation. These data indicate that muscle sympathetic nerve activity is increased by stimulation of chemically sensitive muscle afferents. To determine the influence of central command on muscle sympathetic nerve activity, we compared responses during an involuntary and a voluntary biceps contraction, each at 20% maximal voluntary contraction. Both maneuvers raised arterial pressure, but heart rate increased only during voluntary contraction. More importantly, muscle sympathetic nerve activity rose during involuntary contraction, but fell during voluntary effort.(ABSTRACT TRUNCATED AT 250 WORDS)
The Carcinogenic Potency Database: analyses of 4000 chronic animal cancer experiments published in the general literature and by the U.S. National Cancer Institute/National Toxicology Program.
Authors: L S Gold, T H Slone, N B Manley, G B Garfinkel, E S Hudes, L Rohrbach, B N Ames
Journal: Environmental Health Perspectives (1991)

The Carcinogenic Potency Database (CPDB) is an easily accessible, standardized resource of positive and negative long-term animal cancer tests. The CPDB has been published in four earlier papers that include results for approximately 4000 experiments on 1050 chemicals. This paper describes the CPDB: goals, inclusion criteria, fields of information, and published plot format. It also presents an overview of our published papers using the CPDB. The CPDB as published in plot format readily permits comparisons of carcinogenic potency and many other aspects of cancer tests, including for each experiment the species and strain of test animals, the route and duration of compound administration, dose level and other aspects of experimental protocol, histopathology and tumor incidence, TD50 (carcinogenic potency) and its statistical significance, dose response, author's opinion about carcinogenicity, and literature citation. A combined plot of all results from the four separate papers, which is ordered alphabetically by chemical, is available from L. S. Gold, in printed form or on computer tape or diskette. A computer readable (SAS) database is also available. The overview of papers includes descriptions of work on methods of estimating carcinogenic potency, reproducibility of results in near-replicate cancer tests, correlation in potency between species, ranking possible carcinogenic hazards, comparison of positivity and target organ in rats and mice, comparison of mutagens and nonmutagens, proportion of chemicals positive in animal tests, natural compared to synthetic chemicals, and mechanistic issues in interspecies extrapolation.